Geovax Labs Inc. (GOVX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
GeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript
GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants David Dodd - Chairman, President & CEO Mark Reynolds - CFO & Corporate Secretary John Sharkey - Vice President of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Laura Suriel John Vandermosten - Zacks Investment Research, Inc. Presentation Operator Good afternoon, and welcome, everyone, to the GeoVax Third Quarter 2025 Corporate Update Call. My name is Sherry, and I will facilitate today's call.
Geovax Labs Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 3 | $4 | $2.82 | -$1.18 | -29.5% |
 Anthony Scaramucci SkyBridge Capital II LLC | 269,253 | $371,569.01 | $268,175.99 | -$103,393.02 | -27.83% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2 | $2.76 | $1.97 | -$0.79 | -28.62% |
Geovax Labs Inc. (GOVX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Geovax Labs Inc. ever had a stock split?
Geovax Labs Inc. Profile
| Biotechnology Industry | Healthcare Sector | David Alan Dodd CEO | NASDAQ (CM) Exchange | 373678705 CUSIP |
| US Country | 19 Employees | - Last Dividend | 12 Jan 2026 Last Split | 9 Apr 1999 IPO Date |
Overview
GeoVax Labs, Inc. is a clinical-stage biotechnology firm focused on the development of human vaccines and immunotherapies for a broad spectrum of infectious diseases and solid tumor cancers. Utilizing its proprietary modified vaccinia ankara virus-like particle vaccine platform, GeoVax is at the forefront of addressing some of the most pressing health challenges of our time. With a history dating back to its incorporation in 1988, GeoVax has established itself in the biotechnology industry, headquartered in Smyrna, Georgia. Through strategic collaborations and partnerships with notable institutions such as the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the U.S. Department of Defense, Emory University, and the Burnet Institute, GeoVax leverages significant expertise and resources in its vaccine development programs.
Products and Services
- GEO-CM04S1
- Gedeptin
- GEO-CM02
- GEO-ZM02
- GEO-MM02
- Other Infectious Disease Vaccines
A leading vaccine candidate developed by GeoVax, GEO-CM04S1 is currently undergoing a Phase 2 clinical trial aimed at preventing COVID-19. This represents the company's response to the global pandemic and highlights its capabilities in rapidly developing relevant vaccine candidates.
A novel patented product/technology designed for treating solid tumors, with a specific focus on advanced head and neck squamous cell carcinoma. Gedeptin is in a Phase 1/2 clinical trial, underlining GeoVax's commitment to extending its research and development into cancer immunotherapy.
Reflecting GeoVax's commitment to addressing coronaviruses broadly, GEO-CM02 is a pan-coronavirus vaccine candidate, embodying the company's forward-looking approach in preparing for future coronavirus outbreaks.
Currently in preclinical trial, GEO-ZM02 targets the Zika virus, contributing to the global effort to combat Zika and prevent its devastating impacts, particularly in pregnant women and their unborn children.
This candidate is aimed at the treatment of malaria, a disease that continues to cause significant morbidity and mortality worldwide, especially in developing countries. GEO-MM02 signifies GeoVax's endeavor to tackle historically challenging infectious diseases.
GeoVax is also developing vaccines for several other infectious diseases, including treatments for hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa (GEO-LM01). These efforts exemplify the company's broad and impactful approach to vaccine development.
